^
Association details:
| Biomarker: | HR positive + CCNE1 overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer
Published date:
02/07/2023
Excerpt:
We performed mRNA gene expression profiling and correlation with progression-free-survival (PFS) on 455 tumor samples included in the phase III PEARL study, that assigned HR+/HER2- MBC patients to receive palbociclib+ET vs capecitabine....Tumors with high CCNE1 expression (above median) had also worse median PFS with palbociclib+ET (6.2m) than with capecitabine (9.3m); HR:1.55, adjusted p-value=0.0036….
DOI:
10.1158/1078-0432.CCR-22-2206
